The market may extend its upward journey, but sustainability remains the key factor to watch. Below are some short-term trading ideas to consider.
The latest CDC data, which runs through January 3, shows hospitalizations from this year's 'super flu' have surged ...
ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback